Regenerative Medicine Market 2020 Global Trends Evaluation, Geographical Segmentation, and Investment Opportunities till 2026

The MarketWatch News Department was not involved in the creation of this content.

Nov 25, 2020 (AmericaNewsHour) —
The Regenerative Medicine Market report provides an in-depth analysis of the Healthcare & Pharmaceuticals during the forecast period 2017-2026 which consists of the industry overview including the market size, volume, growth rate and recent trends and developments in the market based on historical and current data. The report covers detailed information about the key players, market segments, growth drivers and restraints in the industry. The report delivers an insight into the Regenerative Medicine Market which allows our clients to make informed decisions regarding the growth of their businesses.

The Regenerative Medicine Market is anticipated to reach over USD 79.23 billion by 2026 according to a new research published by Polaris Market Research. In 2017, the cell therapy dominated the global Regenerative Medicine market, in terms of revenue. North America is expected to be the leading contributor to the global market revenue in 2017.
Regenerative medicine is a branch of medicine that regrows, and repairs the damaged cells in the human body. These medicines include the use of stem cells, tissue engineering, that further helps in developing new organ that function smoothly. These medicines have the caliber of developing an entire organ as these cells are multipotent. The cells are majorly isolated from bone marrow, and umbilical cord blood.

Download free Sample of This Strategic Report:- https://www.kennethresearch.com/sample-request-10070801

The regenerative medicine market is primarily driven by the increasing number of individuals suffering from cancer, rising need to monitor and treating these chronic diseases in the limited time. Furthermore, stringent government policies, proper reimbursement policies, and increasing government healthcare expenditure for developing healthcare infrastructure to also boost the market growth in coming years. Also, rising number of organ transplantation, and increasing number of products in pipeline that are waiting for approval create major opportunity for the regenerative medicines in the coming years. However, some of the ethical and religious concerns for the use of stem cells, and lack of proper regulatory for the approval of various drugs would impede the market growth during the forecast period.

North America generated the highest revenue in the Regenerative Medicine market in 2017, and is expected to be the leading region globally during the forecast period. Increasing number of patients suffering from chronic diseases, improved healthcare infrastructure and health facilities, accessibility of healthcare facilities, are the primary factors driving the market growth in this region. While, Asia Pacific to be the fastest growing region in the coming years. The growth in this region is majorly attributed to the developing healthcare infrastructure of the countries like India, & China, and rising awareness for the use of regenerative medicines as an effective treatment option for chronic diseases.

The key players operating in the Regenerative Medicine market include Organogenesis Inc., Vericel Corporation, Osiris Therapeutics, Inc., Stryker Corporation, and NuVasive, Inc., Medtronic Plc., Acelity, Cook Biotech Inc., Integra LifeSciences, and C.R. Bard. These companies launch new products and collaborate with other market leaders

Read more

Digital Medicine Market Size Global Industry Analysis, Segments, Top Key Players, Drivers and Trends to 2026

The MarketWatch News Department was not involved in the creation of this content.

Nov 24, 2020 (Market Insight Reports) —
Selbyville, Delaware. Market Study Report LLC: A comprehensive research study on Digital Medicine market added by Market Study Report LLC provides insights into the market size and growth trends of this industry over the forecast timeline. The study evaluates key aspects of Digital Medicine market in terms of the demand landscape, driving factors and growth strategies adopted by market players.

This report presents a comprehensive overview, market shares, and growth opportunities of Digital Medicine market by product type, application, key manufacturers and key regions and countries.

Digital medicine technology is an innovative technological technique that has bridged the gap among the healthcare and digital technology. Due to advancement in health care, scientific medicine is pioneered the concept of digital medicine that aims in supporting individualized medicine by recognizing the biology of a patient via a wireless sensor technology and other technologies related to mobile health. Digital medicine is more privileged than recent medical practice as it is more effective, precise, feasible and well distributed technology. Growing healthcare expenditure, high penetration of smartphones, along with high percentage of population with chronic diseases are the few factor responsible for high CAGR of the market over the forecast period.

Request Sample copy of this Report @ https://www.marketstudyreport.com/request-a-sample/2495936/?utm_source=Marketwatchtm.com/&utm_medium=AK

Major market player included in this report are:

2Morrow

Ginger

Akili Interactive

Livongo

AliveCor

WellDoc

Mocacare

Proteus Digital Health Voluntis

Omada Health

Digital Medicine Market outlook: Apart from exploring into the various segments, the report clustered on key Digital Medicine Market trends and sectors that are either driving or averting the growth of the Digital Medicine industry. Growth policies and plans are mentioned likewise as producing processes and cost structures also are analyzed. The Digital Medicine Market industry development trends are studied through both secondary and primary sources. Finally, the feasibility of the latest investment comes is assessed and overall analysis conclusions offered in Digital Medicine market analysis report.

The objective of the study is to define market sizes of different segments & countries in recent years and to forecast the values to the coming eight years. The report is designed to incorporate both qualitative and quantitative aspects of the industry within each of the regions and countries involved in the study. Furthermore, the report also caters the detailed information about the crucial aspects such as driving factors & challenges which will define the future growth of the market. Additionally, the report shall also incorporate available opportunities in micro markets for stakeholders to invest along with the detailed analysis of competitive landscape and product offerings of key players. The detailed segments and sub-segment of the market are explained below:

By Type:

Mobile Health

EMR/EHR

Telehealth

Wireless Health

By Application:

Diabetes

Mental Health

Heart Diseases

Others

Research objectives

To study and analyze the global Digital Medicine market size by key regions/countries, type and application, history data from 2016 to 2017, and forecast to 2026.

To understand the

Read more

Global fitness app market size valuation to reach USD 15.96 billion by 2026

Selbyville, Delaware, Nov. 24, 2020 (GLOBE NEWSWIRE) — As per reliable estimates, worldwide fitness app market size is predicted to reach USD 15.96 billion mark by 2026. Rising concerns associated with unhealthy habits, evolving consumer lifestyle, and growing obese population are some of the key factors propelling the market expansion.

The study elaborates on several market segmentations including app type, device type, OS platform type, and regional outlook. Additionally, the document conducts a thorough SWOT analysis of various companies operating in this business sphere.

The research report also analyzes the impact of COVID-19 outbreak on industry expansion graph and valuation in the ensuing years, further allowing for advanced decision-making during investment assessment.

Request Sample copy of this Report @https://www.marketstudyreport.com/request-a-sample/1695317/

The surge in obese population coupled with rising adoption of sedentary lifestyle have resulted in increased pervasiveness of diseases such as hypertension and diabetes. In addition to this, rising per capita income along with increasing awareness pertaining to health and nutrition are stimulating the overall industry outlook.

According to industry analysts, the number of gym and health club memberships has significantly increased in the recent past. Additionally, rising smartphone penetration, widespread adoption of mobile devices, and easy accessibility to high-speed internet are positively impacting the remuneration scale of global fitness app market.

Availability of numerous types of fitness apps such as Sweat: Kayla Itsines Fitness and Runstatic coupled with high concentration of companies are also facilitating the business scenario. In 2015 for instance, Adidas acquired the Austrian company Runstatic in order to improve its overall market share. Thus, focus among major companies towards expanding their product portfolio through innovative launches and strategic collaborations are aiding the expansion of global fitness app market.

Highlighting the regional outlook

Global fitness app industry is bifurcated into North America, Asia-Pacific, Europe, Latin America, and Middle East & Africa. According to authentic estimations, North America is expected to capture majority market share by the year 2026.

Growing population and surging disposable income are favoring the regional market outlook. Moreover, widespread adoption of sedentary lifestyle and rising health concerns have augmented the demand for fitness apps, which in turn is positively swaying the business dynamics in North America.

Meanwhile, Asia-Pacific fitness app market is set to record the highest CAGR through 2026. Factors such as growing purchasing power, rising health cognizance, high concentration of fitness centers, and increasing smartphone penetration have allowed Asia-Pacific to emerge as a major revenue generator for worldwide fitness app market.

To access a sample copy or view this report in detail along with the table of contents, please click the link below:

https://www.marketstudyreport.com/reports/fitness-app-market-share-size-trends-industry-analysis-report-by-app-type-fitness-and-activity-tracking-diet-and-nutrition-by-device-type-smartphones-tablets-wearable-devices-by-gender-by-os-platform-by-region-segment-forecast-2018-2026

Global Fitness App Market by App Type (Revenue, USD Billion, 2015-2026)

  • Medication Adherence
  • Lifestyle Management
  • Nutrition & Diet
  • Disease Management
  • Workout & Exercise Apps

Global Fitness App Market by Device Terrain (Revenue, USD Billion, 2015-2026)

  • Wearable Devices
  • Tablets
  • Smartphones

Global Fitness App Market by OS Platform (Revenue, USD Billion, 2015-2026)

Global Fitness App Market Regional Outlook (Revenue, USD Billion, 2015-2026)

North America

Europe

  • Netherlands
  • Russia
  • Belgium
  • Spain
Read more

Global Regenerative Medicine Market 2020-2025: Opportunities with the Implementation of the 21st Century Cures Act

Dublin, Nov. 24, 2020 (GLOBE NEWSWIRE) — The “Regenerative Medicine Market by Product (Cell Therapies (Autologous, Allogenic), Stemcell Therapy, Tissue-engineering, Gene Therapy), Application (Wound Care, Musculoskeletal, Oncology, Dental, Ocular), Geography – Global Forecast to 2025” report has been added to ResearchAndMarkets.com’s offering.

The Global Regenerative Medicine Market is Projected to Reach USD 17.9 Billion by 2025 from USD 8.5 Billion in 2020, at a CAGR of 15.9% during the Forecast Period.

Market growth is driven by the rising prevalence of chronic diseases, genetic disorders, and cancer; rising investments in regenerative medicine research; and the growing pipeline of regenerative medicine products. However, the high cost of cell and gene therapies and ethical concerns related to the use of embryonic stem cells in research and development are expected to restrain the growth of this market during the forecast period.

The cell therapies segment accounted for the highest growth rate in the regenerative medicine market, by product, during the forecast period

Based on products, the regenerative medicine market is segmented into tissue-engineered products, cell therapies, gene therapies, and progenitor and stem cell therapies. The cell therapies segment accounted for the highest growth rate in the regenerative medicine market in 2019. The increasing adoption of tissue-engineered products for the treatment of chronic wounds and musculoskeletal disorders and the rising funding for the R&D of regenerative medicine products and therapies are the major factors driving the growth of this segment.

Oncology segment accounted for highest CAGR

Based on applications, the regenerative medicine market is segmented into musculoskeletal disorders, wound care, oncology, ocular disorders, dental, and other applications. In 2019, the oncology segment accounted for the highest growth rate. This can be attributed to the rising prevalence of orthopedic diseases, growing geriatric population, increasing number of stem cell research projects, growing number of clinical researches/trials, and the rich pipeline of stem cell products for the treatment of musculoskeletal disorders.

Europe: The fastest-growing region regenerative medicine market

The global regenerative medicine market is segmented into North America, Europe, the Asia Pacific, and Rest of the World. The North America region is projected to grow at the highest CAGR during the forecast period in 2019. The growth in the North American regenerative medicine market can be attributed to rising stem cell banking, tissue engineering, and drug discovery in the region; expansion of the healthcare sector; and the high adoption of stem cell therapy and cell immunotherapies for the treatment of cancer and chronic diseases.

Market Dynamics

Drivers

  • Rising Prevalence of Chronic Diseases, Genetic Disorders, and Cancer
  • Rising Investments in Regenerative Medicine Research
  • Growing Pipeline of Regenerative Medicine Products

Restraints

  • Ethical Concerns Related to the Use of Embryonic Stem Cells in Research & Development
  • High Cost of Cell and Gene Therapies

Opportunities

  • Implementation of the 21st Century Cures Act
  • Rising Demand for Organ Transplantations

Impact of the COVID-19 Pandemic on the Regenerative Medicine Market

Companies Mentioned

  • 3M Group
  • Allergan
  • Amgen, Inc.
  • Anterogen Co., Ltd.
  • APAC Biotech
  • Aspect Biosystems
  • Bluebird Bio
  • Corestem, Inc.
  • Integra Lifesciences Holdings Corporation
  • Kite Pharma
Read more

Global Regenerative Medicine Market 2020-2025: Opportunities with the Implementation of the 21st Century Cures Act – Press Release

Dublin, Nov. 24, 2020 (GLOBE NEWSWIRE) — The “Regenerative Medicine Market by Product (Cell Therapies (Autologous, Allogenic), Stemcell Therapy, Tissue-engineering, Gene Therapy), Application (Wound Care, Musculoskeletal, Oncology, Dental, Ocular), Geography – Global Forecast to 2025” report has been added to ResearchAndMarkets.com’s offering.

The Global Regenerative Medicine Market is Projected to Reach USD 17.9 Billion by 2025 from USD 8.5 Billion in 2020, at a CAGR of 15.9% during the Forecast Period.

Market growth is driven by the rising prevalence of chronic diseases, genetic disorders, and cancer; rising investments in regenerative medicine research; and the growing pipeline of regenerative medicine products. However, the high cost of cell and gene therapies and ethical concerns related to the use of embryonic stem cells in research and development are expected to restrain the growth of this market during the forecast period.

The cell therapies segment accounted for the highest growth rate in the regenerative medicine market, by product, during the forecast period

Based on products, the regenerative medicine market is segmented into tissue-engineered products, cell therapies, gene therapies, and progenitor and stem cell therapies. The cell therapies segment accounted for the highest growth rate in the regenerative medicine market in 2019. The increasing adoption of tissue-engineered products for the treatment of chronic wounds and musculoskeletal disorders and the rising funding for the R&D of regenerative medicine products and therapies are the major factors driving the growth of this segment.

Oncology segment accounted for highest CAGR

Based on applications, the regenerative medicine market is segmented into musculoskeletal disorders, wound care, oncology, ocular disorders, dental, and other applications. In 2019, the oncology segment accounted for the highest growth rate. This can be attributed to the rising prevalence of orthopedic diseases, growing geriatric population, increasing number of stem cell research projects, growing number of clinical researches/trials, and the rich pipeline of stem cell products for the treatment of musculoskeletal disorders.

Europe: The fastest-growing region regenerative medicine market

The global regenerative medicine market is segmented into North America, Europe, the Asia Pacific, and Rest of the World. The North America region is projected to grow at the highest CAGR during the forecast period in 2019. The growth in the North American regenerative medicine market can be attributed to rising stem cell banking, tissue engineering, and drug discovery in the region; expansion of the healthcare sector; and the high adoption of stem cell therapy and cell immunotherapies for the treatment of cancer and chronic diseases.

Market Dynamics

Drivers

  • Rising Prevalence of Chronic Diseases, Genetic Disorders, and Cancer
  • Rising Investments in Regenerative Medicine Research
  • Growing Pipeline of Regenerative Medicine Products

Restraints

  • Ethical Concerns Related to the Use of Embryonic Stem Cells in Research & Development
  • High Cost of Cell and Gene Therapies

Opportunities

  • Implementation of the 21st Century Cures Act
  • Rising Demand for Organ Transplantations

Impact of the COVID-19 Pandemic on the Regenerative Medicine Market

Companies Mentioned

  • 3M Group
  • Allergan
  • Amgen, Inc.
  • Anterogen Co., Ltd.
  • APAC Biotech
  • Aspect Biosystems
  • Bluebird Bio
  • Corestem, Inc.
  • Integra Lifesciences Holdings Corporation
  • Kite Pharma
  • Medipost
Read more

Global Medical Marijuana Market Demand to Show Superior Growth Despite the Spread of COVID-19

The medical marijuana market is poised to grow by USD 22.33 billion during 2020-2024 progressing at a CAGR of over 24% during the forecast period.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201102005680/en/

Technavio has announced its latest market research report titled Global Medical Marijuana Market 2020-2024 (Graphic: Business Wire)

Technavio suggests three forecast scenarios (optimistic, probable, and pessimistic) considering the impact of COVID-19. Download Free Sample Report on COVID-19 Recovery Analysis

The report on the medical marijuana market provides a holistic update, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis.

The report offers an up-to-date analysis regarding the current global market scenario, the latest trends and drivers, and the overall market environment. The market is driven by the increasing production of medical marijuana.

The medical marijuana market analysis includes application and geography landscape. This study identifies the increase in funding for research and production of medical marijuana as one of the prime reasons driving the medical marijuana market growth during the next few years.

This report presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters

The Medical Marijuana Market covers the following areas:

Medical Marijuana Market Sizing

Medical Marijuana Market Forecast

Medical Marijuana Market Analysis

Companies Mentioned

  • Aphria Inc.

  • Aurora Cannabis Inc.

  • Cannabis Sativa, Inc.

  • Canopy Growth Corp.

  • Cronos Group Inc.

  • GW Pharmaceuticals Plc

  • mCig Inc.

  • Medical Marijuana, Inc.

  • United Cannabis Corp.

  • Vivo Cannabis, Inc.

     

Key Topics Covered:

PART 01: EXECUTIVE SUMMARY

PART 02: SCOPE OF THE REPORT

PART 03: MARKET LANDSCAPE

PART 04: MARKET SIZING

PART 05: FIVE FORCES ANALYSIS

PART 06: MARKET SEGMENTATION BY APPLICATION

  • Market segmentation by application

  • Comparison by application

  • Chronic pain – Market size and forecast 2019-2024

  • Nausea – Market size and forecast 2019-2024

  • Others – Market size and forecast 2019-2024

  • Market opportunity by application

PART 07: CUSTOMER LANDSCAPE

PART 08: GEOGRAPHIC LANDSCAPE

  • Geographic segmentation

  • Geographic comparison

  • North America – Market size and forecast 2019-2024

  • Europe – Market size and forecast 2019-2024

  • APAC – Market size and forecast 2019-2024

  • South America – Market size and forecast 2019-2024

  • MEA – Market size and forecast 2019-2024

  • Key leading countries

  • Market opportunity

PART 09: DECISION FRAMEWORK

PART 10: DRIVERS AND CHALLENGES

  • Market drivers

  • Market challenges

PART 11: MARKET TRENDS

  • Increasing number of awareness campaigns

  • Launch of medical marijuana education programs

  • Increase in funding for research and production of medical marijuana

PART 12: VENDOR LANDSCAPE

  • Overview

  • Landscape disruption

  • Competitive scenario

PART 13: VENDOR ANALYSIS

PART 14: APPENDIX

PART 15: EXPLORE TECHNAVIO

About Us

Technavio is a leading global technology research and advisory company. Their research and analysis focuses on emerging market trends and provides actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions. With over 500 specialized analysts, Technavio’s report library consists of more than 17,000 reports and counting, covering 800 technologies, spanning across 50 countries. Their client base consists of enterprises of all

Read more

Global Herceptin Biosimilar Market to Surpass US$ 5.8 Billion by 2027, Says Coherent Market Insights (CMI)

According to Coherent Market Insights, the global herceptin biosimilar market is estimated to be valued at US$ 1.3 billion in 2020 and is expected to exhibit a CAGR of 24.5 % over the forecast period (2020-2027).

Key Trends and Analysis of the Global Herceptin Biosimilar Market:

Key players are focused on obtaining product approvals to strengthen their position in the global herceptin biosimilar market. For instance, in June 2020, Roche Holding AG received the US Food Drug and Administration approval for Phesgo, a fixed-dose combination of Perjeta (pertuzumab) and Herceptin (trastuzumab) with hyaluronidase, a subcutaneous injection with combination with intravenous chemotherapy for treatment of early and metastatic breast cancer.

Moreover, key players are focused on launching products to strengthen their product portfolio in the global herceptin biosimilar market. For instance, in 2019, Samsungbioepis Co,.Ltd, received approval for its first oncology treatment, Ontruzant, a biosimilar of herceptin and received the approval from US Food Drug and Administration. The product is approved for treatment of metastatic HER2-overexpressing BC, early HER2-overexpressing BC, and advanced gastric cancer in the U.S.

Among regions, North America is expected to register highest growth rate due to the increasing prevalence of diseases such as colorectal cancer, breast cancer and lung cancer in women. The US National Library of Medicine’s report published in September 2020 stated that around breast, lung and colorectal cancer accounted for 50% of the overall cancer incidence in women in the US.

Request Sample Copy of this Report @ https://www.coherentmarketinsights.com/insight/request-sample/4258

Key Market Takeaways:

The global herceptin biosimilar market is expected to exhibit a CAGR of 24.5 % over the forecast period owing to the increasing prevalence of diseases such as gastric cancer and breast cancer in females and product approvals and launches in the global herceptin biosimilar market.

Competitive Landscape:

Key players operating in the global herceptin biosimilar market are Amgen Inc., AryoGen Biopharma, Biocon Limited, Celltrion Inc., Pfizer Inc., Merck & Co., Inc., Accord Healthcare Ltd, Gedeon Richter Plc, Genor Biopharma Company Ltd, Mabion SA, Mylan N.V, Roche Holding AG and Samsungbioepis Co,.Ltd.

Buy-Now this Research Report @ https://www.coherentmarketinsights.com/insight/buy-now/4258

Market Segmentation:

  • Global Herceptin Biosimilar Market, By Indication:

    • Breast Cancer

    • Gastric Cancer

    • Others

  • Global Herceptin Biosimilar Market, By Distribution Channel :

    • Hospitals

    • Oncology Centers

    • Others

  • Global Herceptin Biosimilar Market, By Region:

    • North America

    • Latin America

      • By Country:

        • Brazil

        • Mexico

        • Argentina

        • Rest of Latin America

    • Europe

      • By Country:

        • Germany

        • U.K.

        • France

        • Italy

        • Spain

        • Russia

        • Rest of Europe

    • Asia Pacific

      • By Country:

        • China

        • India

        • Japan

        • Australia

        • South Korea

        • ASEAN

        • Rest of Asia Pacific

    • Middle East

      • By Country/Region:

        • GCC

        • Israel

        • Rest of Middle East

    • Africa

      • By Country/Region:

        • South Africa

        • Central Africa

        • North Africa

Related Market Intelligence Report:

Biosimilars Market, by Drug Class (Recombinant Human Growth Hormone, Granulocyte Colony-Stimulating Factor, Insulin, Anticoagulants, Fusion Proteins, Erythropoietin, Monoclonal Antibodies, Follitropin, and Others), by Therapy Type (Oncology, Immunology, Hematology, Hormone Therapy, Metabolic Disorders, and Others), by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Specialty Pharmacies), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) –

Read more

Sports Medicine Device Market Insights (2020 to 2025) – Analysis and Forecast for the Global and Chinese Markets – Press Release

Dublin, Nov. 02, 2020 (GLOBE NEWSWIRE) — The “Sports Medicine Device Market Insights 2020, Analysis and Forecast Global and Chinese Market to 2025, by Manufacturers, Regions, Technology, Product Type” report has been added to ResearchAndMarkets.com’s offering.

This report is a professional and in-depth study on the current state of the global Sports Medicine Device market with a focus on the Chinese market. The report provides key statistics on market of Sports Medicine Device. It is a valuable source of guidance and direction for companies and individuals interested in Sports Medicine Device industry.

Key points of Sports Medicine Device Market Report:
1. The report provides a basic overview of Sports Medicine Device industry including: definition, applications and manufacturing technology.
2. The report explores Global and Chinese major players in Sports Medicine Device market. In this part, the report presents the company profile, product specifications, capacity, production value, and 2015-2020 market shares for each company.
3. The report depicts the global and Chinese total Sports Medicine Device market including: capacity, production, production value, cost/profit, supply/demand and Chinese import/export, by statistical analysis.
4. The global Sports Medicine Device market is further divided by company, by country, and by application/type for the competitive landscape analysis.
5. The report then estimates 2020-2025 development trends, analyse upstream raw materials, downstream demand, and current market dynamics of Sports Medicine Device market.
6. The report makes some important proposals for a new project of Sports Medicine Device Industry before evaluating its feasibility.
7. Overall, the report provides an in-depth insight of 2015-2025 global and Chinese Sports Medicine Device market covering all important parameters.

Main Parameters for this report:

Type Segment:

Companies Covered:

  • Arthrex
  • Smith & Nephew
  • Stryker
  • Depuy Synthes/Johnson & Johnson
  • Zimmer Biomet
  • Karl Storz
  • Conmed
  • Wright
  • Medshape
  • Valeris
  • Rog
  • Aceosteo
  • Asco Medical
  • Atlas Surgical
  • Auxein
  • Biotek
  • Bonetech Medisys
  • CHM
  • Egifix
  • Forerunner
  • Fxorthopedi
  • Gesco Medical
  • GPC Medical Ltd
  • Green Surgical
  • Griphorto
  • Hardik International
  • HIBS
  • Innomed Solutions
  • Jeil Medical
  • Jiangsu Bai De Medical Instrument
  • Marapole
  • Matrix
  • Medgal
  • Microport
  • Miraclus
  • Narang
  • Naton Group
  • Nebula

Key Topics Covered:

1.: Introduction of Sports Medicine Device Industry
1.1 Brief Introduction of Sports Medicine Device
1.2 Development of Sports Medicine Device Industry
1.3 Status of Sports Medicine Device Industry

2.: Manufacturing Technology of Sports Medicine Device
2.1 Development of Sports Medicine Device Manufacturing Technology
2.2 Analysis of Sports Medicine Device Manufacturing Technology
2.3 Trends of Sports Medicine Device Manufacturing Technology

3.: Analysis of Global Key Manufacturers
3.1 Arthrex
3.1.1 Company Profile
3.1.2 Product Information
3.1.3 Capacity Production Price Cost Production Value
3.1.4 Contact Information
3.2 Smith & Nephew
3.2.1 Company Profile
3.2.2 Product Information
3.2.3 Capacity Production Price Cost Production Value
3.2.4 Contact Information
3.3 Stryker
3.3.1 Company Profile
3.3.2 Product Information
3.3.3 Capacity Production Price Cost Production Value
3.3.4 Contact Information
3.4 Depuy Synthes/Johnson & Johnson
3.4.1 Company Profile
3.4.2 Product Information
3.4.3 Capacity Production Price Cost Production Value
3.4.4 Contact Information
3.5 Zimmer Biomet
3.5.1 Company Profile
3.5.2 Product Information
3.5.3 Capacity Production Price Cost Production Value
3.5.4 Contact Information
3.6 Karl

Read more

Global Personalized Medicine Scientific & Commercial Aspects Market Report 2020-2029 with Profiles of 298 Companies Along with 583 Collaborations

Dublin, Oct. 30, 2020 (GLOBE NEWSWIRE) — The “Personalized Medicine – Scientific & Commercial Aspects” report from Jain PharmaBiotech has been added to ResearchAndMarkets.com’s offering.

The concept of personalized medicine described in this report remains remains the best way to integrate new technologies such as nanobiotechnology for improving healthcare.

Increase in efficacy and safety of treatment by individualizing it has benefits in financial terms. Information is presented to show that personalized medicine will be cost-effective in healthcare systems. For the pharmaceutical companies, segmentation of the market may not leave room for conventional blockbusters but smaller and exclusive markets for personalized medicines would be profitable. Marketing opportunities for such a system are described with market estimates from 2019-2029.

Profiles of 298 companies involved in developing technologies for personalized medicines, along with 583 collaborations are included.
The aim of personalized medicine or individualized treatment is to match the right drug to the right patient and, in some cases, even to design the appropriate treatment for a patient according to his/her genotype. This report describes the latest concepts of development of personalized medicine based on pharmacogenomics, pharmacogenetics,pharmacoproteomics, and metabolomics.

Basic technologies of molecular diagnostics play an important role, particularly those for single nucleotide polymorphism (SNP) genotyping. Biomarkers play an important role in personalized medicine. Diagnosis is integrated with therapy for selection of treatment as well for monitoring the results. There is emphasis on early detection and prevention of disease in modern medicine. Biochip/microarray technologies and next generation sequencing are also important.

Pharmacogenetics, the study of influence of genetic factors on drug action and metabolism, is used for predicting adverse reactions of drugs. Several enzymes are involved in drug metabolism of which the most important ones are those belonging to the family of cytochrome P450. The knowledge of the effects of polymorphisms of genes for the enzymes is applied in drug discovery and development as well as in clinical use of drugs. Cost-effective methods for genotyping are being developed and it would be desirable to include this information in the patient’s record for the guidance of the physician to individualize the treatment.

Pharmacogenomics, a term that overlaps with pharmacogenetics but is distinct, deals with the application of genomics to drug discovery and development. It involves the mechanism of action of drugs on cells as revealed by gene expression patterns. Pharmacoproteomics is an important contribution to personalized medicine as it is a more functional representation of patient-to-patient variation than that provided by genotyping.A ‘pharmacometabonomic’ approach to personalizing drug treatment is also described.

Biological therapies such as those which use patient’s own cells are considered to be personalized medicines. Vaccines are prepared from individual patient’s tumor cells. Individualized therapeutic strategies using monoclonal bodies can be directed at specific genetic and immunologic targets. Ex vivo gene therapy involves the genetic modification of the patient’s cells in vitro, prior to reimplantation of these cells in the patient’s body.

Various technologies are integrated to develop personalized therapies for specific therapeutic areas described in the report. Examples of

Read more

U.S. Hits Record as Global Cases Top 45 Million: Virus Update

(Bloomberg) — U.S. new cases topped 89,000, setting a daily record, as the outbreak intensifies ahead of next week’s presidential election. Global infections surpassed 45 million, with Europe also grappling to control a renewed surge in the disease across the continent.

Loading...

Load Error

German cases exceeded 500,000 after a gain of more than 19,000 through early Friday, confirming a trend that Chancellor Angela Merkel has characterized as a “dramatic situation.” France’s economy staged a record rebound in the third quarter, but that recovery now risks being derailed by new government restrictions. Poland is set to announce new measures to curtail its outbreak and Ukraine reported records in both deaths and infections.

In the U.S., infections are again on the rise in New York and New Jersey, while Midwest states are suffering a record outbreak. Anthony Fauci, the government’s top infectious disease doctor, predicted it could take until the end of 2021 at least for U.S. social life to return to normal even with an effective vaccine.

Key Developments:

Global Tracker: Cases surpass 45 million; deaths topped 1.18 millionMnuchin faults Pelosi as stimulus blame game heats upOperation Warp Speed could shape up to be an $18 billion bargainECB pushes governments to get on with spending in virus battleHow do people catch Covid-19?: QuickTakeVaccine Tracker: Clinical trials restart, providing hope

Subscribe to a daily update on the virus from Bloomberg’s Prognosis team here. Click CVID on the terminal for global data on coronavirus cases and deaths.

Sweden Earmarks More Cash for Testing (2:50 p.m. HK)

Sweden’s government has underestimated the cost of testing and tracing Covid-19 patients and the money that’s been earmarked for the purpose is now running out, TV4 reports.

The government will allocate an extra 3 billion kronor ($336 million) to pay for testing through the end of the year, bringing the total cost for testing and infection tracing this year to almost 10 billion kronor, according to the report.

Poland to Announce Restrictions on Friday (2:45 p.m. HK)

Poland’s health-care system is “stretched to its limits,” Michal Dworczyk, chief of staff in Prime Minister Mateusz Morawiecki’s office, says in interview with public radio 1.

Morawiecki has asked biggest state-run companies to build temporary hospitals in order to add more than 3,000 beds to treat Covid-19 patients.

Swiss Re Adds $500 Million to Reserves (2:31 p.m. HK)

Swiss Re added another $500 million in reserves for future claims as it warned about the high uncertainty that remains because of the coronavirus pandemic.

The re-insurer reported a net loss of $691 million for the first nine months of the year, driven by the increase in reserves it had to take for future claims, as the virus resurges and the threat of more lockdowns looms.

Lonza, AstraZeneca to Manufacture Antibody Combination (2:19 p.m. HK)

Lonza and AstraZeneca agreed to manufacture a combination of two long-acting antibodies for Covid-19 treatment called AZD7442, according to an SGX filing.

AZD7442 is currently in Phase 1 clinical studies and AstraZeneca plans to advance it into

Read more